GLOMERULONEPHRITIS, IGA
Clinical trials for GLOMERULONEPHRITIS, IGA explained in plain language.
Never miss a new study
Get alerted when new GLOMERULONEPHRITIS, IGA trials appear
Sign up with your email to follow new studies for GLOMERULONEPHRITIS, IGA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kidney disease: Long-Term drug safety trial launches
Disease control Recruiting nowThis study looks at the long-term safety of a drug called zigakibart for adults with IgA nephropathy, a kidney disease. It is for people who have already finished another zigakibart study. The goal is to see if the drug remains safe and helpful over time.
Matched conditions: GLOMERULONEPHRITIS, IGA
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 07:39 UTC
-
New drug iptacopan under microscope in kidney biopsy study
Knowledge-focused Recruiting nowThis study looks at how the drug iptacopan affects the kidneys of 20 adults with IgA nephropathy, a kidney disease. Researchers will use kidney biopsies and lab tests to measure changes in immune system activity and kidney damage over 9 months. The goal is to understand how iptac…
Matched conditions: GLOMERULONEPHRITIS, IGA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated May 15, 2026 11:53 UTC